Abstract:BACKGROUND:Entecavir (ETV) is a potent and selective nucleotide analog with significant activity against hepatitis B virus (HBV). ETV maleate is a derivative compound of ETV and was reported to have an efficacy and safety profile that is comparable to ETV (Baraclude) when used in Chinese patients with chronic hepatitis B (CHB) in phase III clinical trials (Clinical Trials.gov number, NCT01926288) at weeks 48, 96, and 144. AIM:To investigate the antiviral potency and safety of ETV maleate at week 192 in Chinese CHB patients predominantly genotyped B or C. METHODS:In this double-blind study, we randomly assigned patients to receive 0.5 mg/d ETV (Group A) or ETV maleate (Group B) (ratio, 1:1), each with a placebo tablet for 48 wk. Then, all patients received open-label treatment with 0.5 mg/d ETV maleate starting at week 49. The primary efficacy endpoint was the reduction in HBV DNA levels from baseline. Secondary endpoints included the proportion of patients with undetectable HBV DNA (< 20 IU/mL), serologic response, serum alanine aminotransferase (ALT) normalization and development of resistance mutations. RESULTS:Two hundred eighteen patients who were hepatitis B e antigen (HBeAg) positive and 57 who were HBeAg negative were analyzed and predominantly presented with genotype B (49.82%) or C (48.73%). For the HBeAg-positive CHB patients, the mean HBV DNA level decrease (6.61 Log10 IU/mL vs 6.69 Log10 IU/mL, P > 0.05), viral suppression with HBV DNA < 20 IU/mL (83.33% vs 79.17%, P > 0.05) and HBeAg seroconversion (28.77% vs 20.00%, P > 0.05) occurred similarly between Groups A and B at week 192. However, there was a significant difference in the proportion of patients with normal ALT levels (91.14% vs 78.38%, P < 0.05). For the HBeAg-negative CHB patients, no significant difference was found between Groups A and B at week 192 in terms of reductions in HBV DNA levels from baseline (6.05 Log10 IU/mL vs 6.03 Log10 IU/mL, P > 0.05), percentages of patients who achieved undetectable HBV DNA (100% vs 100%, P > 0.05) and rates of ALT normalization (95.65% vs 100.00%, P > 0.05). Safety and adverse event profiles were similar between Groups A and B. Two HBeAg-positive patients in Group A and 5 in Group B developed genotypic resistance to ETV. CONCLUSION:Long-term ETV maleate treatment for up to 192 wk is effective and safe in Chinese CHB patients predominantly genotyped as B or C.

Pregnancy Impacts Entecavir Pharmacokinetics but Does Not Alter Its Renal Excretion

Roles of Organic Anion Transporter 2 and Equilibrative Nucleoside Transporter 1 in Hepatic Disposition and Antiviral Activity of Entecavir During Non-Pregnancy and Pregnancy.

Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir

Safety of Entecavir Antiviral Therapyduring an Accidental Pregnancy in Patients with Chronic Hepatitis B.

Safety of Efavirenz in First-trimester of Pregnancy

The effects of accident pregnancy CHB patients’ reproductive age on their offspring during entecavir antiviral therapy: an observational study

Pregnancy Outcomes for Pregnant Women with Chronic Hepatitis B Exposing to Entecavir or Adefovir Dipivoxil Therapy Before or in Early Pregnancy

Safety of Anti-hepatitis B Virus Therapy During Pregnancy and Lactation

Effect of Prophylactic Antiviral Intervention on T Cell Immunity in Hepatitis B Virus-Infected Pregnant Women

Multiple Drug Transporters Are Involved in Renal Secretion of Entecavir

[Analysis of a Randomized, Double-Blind, Double-Dummy, Controlled, Multicenter Study Confirmed the Similar Therapeutic Efficacies of Entecavir Maleate and Entecavir for Treatment of HBeAg-positive Chronic Hepatitis B].

A randomized, double-blind, double-dummy, controlled, multicenter study of entecavir maleate versus entecavir for treatment of HBeAg-negative chronic hepatitis B: results at week 48

One Hundred and Ninety-Two Weeks Treatment of Entecavir Maleate for Chinese Chronic Hepatitis B Predominantly Genotyped B or C

[A Survey of the Current Status of Research on the Diagnosis and Treatment of Hepatitis C Virus Antibody-Positive Pregnant Women].

A randomized, double-blind, double-dummy, controlled, multicenter study of entecavir maleate versus entecavir for treatment of chronic hepatitis B: results at week 96

High Prevalence of Preexisting HBV Polymerase Mutations in Pregnant Women Does Not Limit the Antiviral Therapy Efficacy.

Increased estradiol in hepatitis E virus infected pregnant women promote viral replication.

Potential Effects of Telbivudine Versus Entecavir on Renal Function in Patients with Chronic Hepatitis B Virus Receiving Glucocorticoids Therapy.

Clinical Application of Entecavir for Treating Adefovir Ester Resistant Chronic Hepatitis B

Physiologically Based Pharmacokinetic Models to Predict Maternal Pharmacokinetics and Fetal Exposure to Emtricitabine and Acyclovir

High prevalence of pre-existing HBV polymerase mutations in pregnant women do not limit the telbivudine treatment efficacy